Edition:
United Kingdom

People: Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

8.27USD
19 Jul 2019
Change (% chg)

-- (--)
Prev Close
$8.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
55,398
52-wk High
$11.44
52-wk Low
$6.20

Blouse, Grant 

Dr. Grant Blouse is Vice President - Translational Research of the Company. Dr. Blouse was most recently principle scientist and project manager at Novo Nordisk A/S, Haemophilia Enzymology, where he led early and late stage hemophilia projects and drove the strategic evaluation of new therapeutic areas in the rare disease space. Prior to Novo Nordisk, Dr. Blouse was a senior scientist at Catalyst Biosciences where he helped to build Catalyst's next-generation hemophilia franchise, including helping to identify Catalyst's Factor VIIa candidate marzeptacog alfa (activated) and co-inventing its Factor IX candidate CB 2679d/ISU304. Dr. Blouse has held research and investigator positions at Aarhus University's Department of Molecular Biology, Henry Ford Health System's Division of Biochemical Research and Wayne State University School of Medicine's Department of Pharmacology. He has authored more than 50 peer reviewed papers and abstracts and delivered more than a dozen invited talks in the biochemistry and hematology spaces. Dr. Blouse earned his B.A. in anthropology from the University of Delaware, his M.Sc. in biochemistry from Clemson University and his Ph.D. in pharmacology from Wayne State University School of Medicine.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --